FDA Grants Rein Therapeutics Fast Track Designation For LTI-03

Benzinga · 1d ago
  • Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression
    • Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026